Pharmapriser ApS (CVR 36479868) Company Profile

Ownership

JF Consolidated ApS
CVR 3948083250% to under 66.7% of capital and votesnotified 21 Aug 2026since 16 Apr 2018

Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.

Former owners (5)

Christian Frisch
50% to under 66.7% of capital and votesnotified 2 Feb 202423 Jan 2024 to 2 Feb 2024
Oscar Thalund-Jørgensen
50% to under 66.7% of capital and votesnotified 21 Aug 202625 Jan 2024 to 21 Aug 2026
LES DEUX ApS
CVR 3350646550% to under 66.7% of capital and votesnotified 16 Apr 201830 Dec 2014 to 16 Apr 2018
AXELTOFT HOLDING ApS
CVR 3647983325% to under 33.3% of capital and votesnotified 16 Apr 201830 Dec 2014 to 16 Apr 2018
CF Equity Group ApS
CVR 4119471550% to under 66.7% of capital and votesnotified 21 Aug 202623 Jan 2024 to 21 Aug 2026

Control Chain

Ultimate controller
Jacob Frisch
Holds 100% of capital and votes in JF Consolidated ApS, since 9 Apr 2018
Capital100%
Votes100%
Holding company
JF Consolidated ApS
CVR 39480832Private limited company (ApS)
Holds 50% to under 66.7% of capital and votes in Pharmapriser ApS, since 21 Aug 2026
Capital50% to under 66.7%
Votes50% to under 66.7%
This company
Pharmapriser ApS
CVR 36479868

Each holds the one below it. Control follows votes: an owner with 50% or more controls. Each bar shows the registered band, solid to its lower bound and faint across the range CVR records, with a mark at 50%. Dandex estimate, computed 10 Nov 2026.

Dandex Estimates

Legal ownership resolution (Ejerforholdenes opløsning): Ends at a personThe chain of majority owners ends at a person, through 1 company; legal owners in the CVR owner register only. Dandex estimate, rule v3, computed 10 Nov 2026.
Control tenure (Ejerskabsperiode): Pro: in the Pro plan, see pricingHow long the current ultimate controller has held control, from the CVR owner register.
Group position (Koncernforhold): Has a parent, and no majority holding in a Danish companyControlled by a company in CVR; it holds 50% or more of no Danish company. Dandex estimate, rule v2, computed 10 Nov 2026.
Holding company assets (Holdingselskabets aktiver): Pro: in the Pro plan, see pricingFor a holding company, the kind of asset that makes up half its balance sheet or more.
Signing authority, structured (Tegningsregel, struktureret): Two people must act togetherThe registered signing rule needs at least two people acting together; current members: executive board 2. Dandex estimate, rule v2, computed 10 Nov 2026.

Decided by Dandex with fixed rules from the CVR register and the filed annual reports, not registered by the company. Each label links to its definition.

People

Current (2)

Christian FrischExecutive board since 3 Feb 2024
Oscar Thalund-JørgensenExecutive board since 3 Feb 2024

Founders (3)

AXELTOFT HOLDING ApSFounded 30 Dec 2014
DELANEY HOLDING ApSFounded 30 Dec 2014
LES DEUX ApSFounded 30 Dec 2014

CVR records founders at incorporation. It does not record whether they are alive or still involved.

Former (2)

Mads Klixbüll-AxeltoftExecutive board 30 Dec 2014 to 16 Apr 2018
Jacob FrischExecutive board 16 Apr 2018 to 3 Feb 2024

Network

Roles Over Time

Christian Frisch: Executive board, 3 Feb 2024 to today.
Oscar Thalund-Jørgensen: Executive board, 3 Feb 2024 to today.

3 Feb 2024 to 10 Nov 2026.

Former (2)

Jacob Frisch: Executive board, 16 Apr 2018 to 3 Feb 2024.
Mads Klixbüll-Axeltoft: Executive board, 30 Dec 2014 to 16 Apr 2018.

30 Dec 2014 to 10 Nov 2026.

Executive board (Direktion)Each bar is one role, from its start to its end or today. Bars in a group share one scale. Source: CVR.

Network

Headcount

CVR holds no employment figures for this company.

Financials

Annual report figures by year, DKK thousands
Metric	2021	2022	2023	2024	2025
Revenue	78	87	10	Not reported	Not reported
Gross profit	Not reported	Not reported	Not reported	-1	-6
Operating profit	+24	+17	-24	-1	-7
Result for the year	+19	+17	-36	-2	-8
Equity	-41	105	-74	48	40
Total assets	105	105	69	52	40
Credit metrics (Dandex calculations)
Revenue growth (omsætningsvækst)	77.7%	11.6%	-88.2%	Not reported	Not reported
EBIT margin (overskudsgrad)	31%	19.1%	-229.4%	Not reported	Not reported
EBITDA	24	17	-8	-1	Not reported^{note 1}
EBITDA margin	31%	19.1%	-81.5%	Not reported	Not reported
Net interest-bearing debt (NIBD, nettorentebærende gæld)	Pro: in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash.
Gearing, NIBD / EBITDA	Pro: in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes.
Interest coverage (rentedækning)	Pro: in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest.
Adjusted equity ratio (justeret soliditetsgrad)	Pro: in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis.
ROIC (afkast af investeret kapital)	Pro: in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt.
Capex (investeringer i anlægsaktiver)	Not reported^{note 2}	5^{note 3}	0^{note 3}	0^{note 3}	Not reported^{note 4}
Capex % of sales (investeringer i procent af omsætningen)	Pro: in the Pro plan, see pricingCapex as a share of revenue.
FCFF / EBITDA (pengestrømskonvertering)	Pro: in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA.

DKK thousands. Annual reports via XBRL.

Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions.

1 no depreciation line filed
2 disposals exceed investment
3 Dandex estimate: capex from the balance sheet change plus D&A
4 no capex filed

Credit rating (kreditvurdering): Pro: in the Pro plan, see pricingA score from 0 to 100.
Capital loss (kapitaltab): Pro: in the Pro plan, see pricingNegative equity, or equity below half the share capital, in the latest report.
Filing deadline and punctuality (indsendelsesfrist): Pro: in the Pro plan, see pricingThe next annual report deadline.

Annual Reports

Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 20 Jun 2026
XHTML
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 25 May 2025
XHTML
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 30 Jun 2024
XHTML
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 3 Jul 2023
XHTML
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 30 Jun 2022
XHTML

Financials

Changes

All changes

21 Aug 2026
Name change
Pharmapriser ApS (CVR 36479868) har skiftet navn fra "MAIN COPENHAGEN ApS" til "Pharmapriser ApS" pr. 21. august 2026.
6 May 2026
Ownership change
MAIN COPENHAGEN ApS (CVR 36479868) har foretaget ejerskifte pr. 6. maj 2026: 4 indtrådt.
3 Feb 2024
Director change
MAIN COPENHAGEN ApS (CVR 36479868) har foretaget direktørskifte pr. 3. februar 2024: 1 indtrådt.
3 Feb 2024
Director change
MAIN COPENHAGEN ApS (CVR 36479868) har foretaget direktørskifte pr. 3. februar 2024: 1 indtrådt.
25 Jan 2024
Ownership change
MAIN COPENHAGEN ApS (CVR 36479868) har foretaget ejerskifte pr. 25. januar 2024: 2 indtrådt.
16 Apr 2018
Director change
MAIN COPENHAGEN ApS (CVR 36479868) har foretaget direktørskifte pr. 16. april 2018: 1 indtrådt.
30 Dec 2014
Director change
MAIN COPENHAGEN ApS (CVR 36479868) har foretaget direktørskifte pr. 30. december 2014: 1 indtrådt.

Signals (signaler)

Pro: in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.

New leadership (Nyt lederskab), New company (Ny virksomhed), Ownership change (Ejerskifte), Relocation (Flytning), Growth surge (Vækstspurt), Headcount decline (Nedgang i ansatte), Restructuring (Omstrukturering), Industry change (Brancheskift), Board change (Bestyrelsesændring), Dissolution (Ophør), Distress warning (Risikoadvarsel), Fund investment (Fondsinvestering), Fund exit (Fondsexit), Fund board seat (Fondsbestyrelsespost).

Changes

Pro for This Company

The rows marked Pro on this page hold values in the Pro plan. For Pharmapriser ApS, that is:

Credit and debt: Net interest-bearing debt, gearing, NIBD / EBITDA, interest coverage and adjusted equity ratio, for 2021 to 2025.Credit rating, capital loss and filing deadline and punctuality.
Returns and cash flow: ROIC, capex % of sales and FCFF / EBITDA, for 2021 to 2025.
Advanced estimates: Control tenure and holding company assets.
Signals and monitoring: Signals on this company, as Dandex raises them.

See the Pro plan

Have Pro? Sign in to see the values on this page.

Registry Facts

Signing rule (Tegningsregel): Selskabet tegnes af den samlede direktion.since 25 Apr 2018
Purpose (Formål): Selskabets formål er at fungere som tøjvirksomhed og samt anden virksomhed, der efter direktionens skøn er forbundet dermed.since 25 Apr 2018
Audit opted out (Revision fravalgt): Yessince 30 Dec 2014
Articles of association last changed (Seneste vedtægtsdato): 21 Aug 2026

Share Capital

Each registered value from the day it took effect, newest first.

30 Dec 201450,000 DKKEarliest in CVR

From CVR, read 10 Nov 2026. Text such as the signing rule and purpose is shown as registered.

Registry Facts

Registrations (Registreringer)

6 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.

21 Aug 2026
Other
Vedtægter ændret: 21.08.2026
Nyt navn: Pharmapriser ApS
Slettede binavne: Main Underwear ApS, Mains Copenhagen ApS, Main CPH ApS, Main Loungewear ApS, Main Wonderwear ApS
17 Jul 2024
Other People change
Vedtægter ændret: 17.07.2024
Nye binavne: Main Underwear ApS, Mains Copenhagen ApS, Main CPH ApS, Main Loungewear ApS, Main Wonderwear ApS
Direktion:
Fratrådte:
Oscar Thalund-Jørgensen, (adm. dir), den 17.07.2024.
Tiltrådte:
Oscar Thalund-Jørgensen, den 17.07.2024.
3 Feb 2024
People change
Direktion:
Fratrådte:
Jacob Frisch, den 03.02.2024.
Tiltrådte:
Christian Frisch, den 03.02.2024, Oscar Thalund-Jørgensen, (adm. dir), den 03.02.2024.
25 Apr 2018
People change
Vedtægter ændret: 24.04.2018
Direktion:
Fratrådte:
Mads Axeltoft, den 16.04.2018.
Tiltrådte:
Jacob Frisch, den 16.04.2018.
Selskabet tegnes af den samlede direktion..
Formål ændret: Selskabets formål er at fungere som tøjvirksomhed og samt anden virksomhed, der efter direktionens skøn er forbundet dermed.
24 Apr 2018
Address change
Ny adresse: Hambros Alle 11C, 2900 Hellerup
Ny kommune: Gentofte
6 Jan 2015
New company
Stiftelsesdato:
30.12.2014.
Seneste vedtægtsdato:
30.12.2014.
Kapital:
kr. 50.000,00.
Show the full announcement
Indbetalingsmåde:
Indbetalt kontant kr. 50.000,00 til kurs 100,00.
Stiftere:
CVR-NR. 33506465 LES DEUX ApS, Nordre Strandvej 48B, Højstrup, 3000 Helsingør, den 30.12.2014, CVR-NR. 36479833 AXELTOFT HOLDING ApS, Frederiksberg Alle 5, 2. tv., 1621 København V, den 30.12.2014, CVR-NR. 36479841 DELANEY HOLDING ApS, Madvigs Alle 4, 4. th., 1829 Frederiksberg C, den 30.12.2014.
Direktion:
Mads Axeltoft, den 30.12.2014.
Selskabet tegnes af 1 direktør i forening.
Første regnskabsår:
30.12.2014 - 31.12.2015.
Regnskabsår:
01.01 - 31.12.

Registrations (Registreringer)

Registration

Address: Hambros Alle 11
2900 Hellerup
Gentofte Municipality
CVR record last changed: 23 Oct 2026
Data read: 10 Nov 2026

Production Units

1 registered in CVR.

Pharmapriser ApS
P-number 1020029885Hambros Alle 11, 2900 Hellerup

Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.

Ownership

People

Network

Headcount

Financials

Changes

Registry Facts

Registrations (Registreringer)

Registration

Dandex in Your Own Tools

Ownership

People

Financials

Who Is Behind It

Ownership

Control Chain

Dandex Estimates

People

Current (2)

Founders (3)

Network

Roles Over Time

Network

Headcount

Financials

Annual Reports

Financials

Changes

Signals (signaler)

Changes

Pro for This Company

Registry Facts

Share Capital

Registry Facts

Registrations (Registreringer)

Registrations (Registreringer)

Registration

Production Units

Dandex in Your Own Tools

Who Is Behind It

Control Chain

Dandex Estimates

Current (2)

Founders (3)

Network

Owners and the control chain

Its people and their other companies

Network

Roles Over Time

Financials

Annual Reports

Changes

Signals (signaler)

Pro for This Company

Registry Facts

Share Capital

Registrations (Registreringer)

Production Units

Network

Owners and the control chain

Its people and their other companies